Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome

by Parc Científic de Barcelona

Avizorex Pharma –an ophthalmology biotech company with offices at Barcelona Science Park (PCB)– announcesthe submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority, re...

Read more

Avizorex Pharma submits clinical trial application for its lead compound AVX-012 for dry eye syndrome

by Inveready

AVX-012, a Small Molecule with a novel mechanism of action, to be investigated as a potential new treatment for mild to moderate Dry Eye Syndrome.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream